- Home
- PTCT
PTCT
PTC Therapeutics Inc.
as 01-22-2025 4:00pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | WARREN |
| Market Cap: | N/A | IPO Year: | 2013 |
| Target Price: | $52.77 | AVG Volume (30 days): | 566.9K |
| Analyst Decision: | Hold | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.93 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.58 - $54.16 | Next Earning Date: | 02-27-2025 |
| Revenue: | $900,664,000 | Revenue Growth: | 12.84% |
| Revenue Growth (this year): | -13.68% | Revenue Growth (next year): | 14.26% |
Stock Insider Trading Activity of PTC Therapeutics Inc. (PTCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Jan 7 '25 | Sell | $44.92 | 4,544 | $204,007.28 | 286,232 | |
| Pauwels Eric | PTCT | CHIEF EXECUTIVE OFFICER | Jan 7 '25 | Sell | $44.92 | 3,735 | $167,550.66 | 88,941 | |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Jan 7 '25 | Sell | $44.92 | 2,979 | $133,674.30 | 103,231 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Jan 7 '25 | Sell | $44.92 | 3,541 | $158,870.62 | 108,846 | |
| Golden Lee Scott | PTCT | EVP & CHIEF MEDICAL OFFICER | Jan 7 '25 | Sell | $44.92 | 2,008 | $90,036.40 | 79,849 | |
| Klein Matthew B. | PTCT | CHIEF EXECUTIVE OFFICER | Dec 31 '24 | Sell | $45.16 | 8,279 | $373,879.64 | 286,232 | |
| Utter Christine Marie | PTCT | SVP, CHIEF ACCOUNTING OFFICER | Dec 2 '24 | Sell | $51.89 | 17,800 | $921,585.17 | 52,428 | |
| Almstead Neil Gregory | PTCT | CHIEF TECHNICAL OPS OFFICER | Dec 2 '24 | Sell | $52.31 | 71,610 | $3,727,957.62 | 103,231 | |
| ZELDIS JEROME B | PTCT | Director | Dec 2 '24 | Sell | $51.64 | 24,000 | $1,235,897.49 | 14,500 | |
| Boulding Mark Elliott | PTCT | EXEC. VP AND CLO | Dec 2 '24 | Sell | $53.13 | 95,908 | $5,022,334.27 | 108,846 |
Latest PTC Therapeutics Inc. News
PTCT Breaking Stock News: Dive into PTCT Ticker-Specific Updates for Smart Investing
PR Newswire
9 days ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire
10 days ago
PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
16 days ago
RBC Cuts Price Target on PTC Therapeutics to $58 From $63, Keeps Outperform Rating
PR Newswire
a month ago
PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MT Newswires
a month ago
PTC Therapeutics Files NDA With US FDA for Vatiquinone to Treat Friedreich's Ataxia
PR Newswire
a month ago
PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
PR Newswire
a month ago
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Morgan Stanley Upgrades PTC Therapeutics to Overweight From Equalweight, Raises Price Target to $67 From $45
Compare PTCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTCT PTC Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.